Bruce Alan Sullenger
Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery
The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.
The specific aims of my laboratory are:
1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.
2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.
3. To reprogram cells using mRNA delivery.
4. To explore novel methods to control inflammation.
The specific aims of my laboratory are:
1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.
2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.
3. To reprogram cells using mRNA delivery.
4. To explore novel methods to control inflammation.
Current Appointments & Affiliations
- Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Surgical Sciences, Surgery 2003
- Professor in Surgery, Surgery, Surgical Sciences, Surgery 2001
- Director of the Duke Center for Translational Research, Surgery, Clinical Science Departments 2004
- Professor of Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2012
- Professor of Neurosurgery, Neurosurgery, Neurosurgery 2019
- Professor of Cell Biology, Cell Biology, Basic Science Departments 2022
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1994
Contact Information
- 120 Serrano Way, Chapel Hill, NC 27517
- Box 103035, Durham, NC 27710
-
bruce.sullenger@duke.edu
(919) 451-8921
- Background
-
Education, Training, & Certifications
- Ph.D., Cornell University 1990
-
Previous Appointments & Affiliations
- Core Faculty in Innovation & Entrepreneurship, Duke Innovation & Entrepreneurship, Initiatives 2018 - 2021
- Associate Professor in Molecular Genetics and Microbiology, Molecular Genetics and Microbiology, Basic Science Departments 2002 - 2020
- Associate Professor in Genetics, School of Medicine, Duke University 2000 - 2002
- Associate Professor in Surgery, Surgery, Surgical Sciences, Surgery 1999 - 2001
- Assistant Professor in Genetics, School of Medicine, Duke University 1994 - 2000
- Assistant Professor of Surgery, Surgery, Surgical Sciences, Surgery 1994 - 1998
- Recognition
-
In the News
-
Awards & Honors
- Research
-
Selected Grants
- Stimulating Access to Research in Residency (StARR) - NHLBI awarded by National Institutes of Health 2018 - 2028
- Medical Scientist Training Program awarded by National Institutes of Health 2022 - 2027
- University Training Program in Biomolecular and Tissue Engineering awarded by National Institutes of Health 1994 - 2027
- Cell and Molecular Biology Training Program awarded by National Institutes of Health 2021 - 2026
- Hematology & Transfusion Medicine (T32) awarded by National Institutes of Health 1975 - 2026
- Genetic and Genomics Training Grant awarded by National Institutes of Health 2020 - 2025
- Pharmacological Sciences Training Grant awarded by National Institutes of Health 2020 - 2025
- NINDS Research Education Programs for Residents and Fellows in Neurosurgery awarded by National Institutes of Health 2009 - 2025
- Targeting mitochondrial dysfunction and damage-associated molecular patterns to improve the function of high risk grafts in liver transplantation awarded by National Institutes of Health 2020 - 2025
- Aptamer-small molecule conjugate as potent and reversible surgical anticoagulants awarded by American Heart Association 2023 - 2024
- Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2024
- Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2024
- Advanced Immunobiology Traning Program for Surgeons awarded by National Institutes of Health 2019 - 2024
- Cas9 RNP delivery to immune cells in vivo via molecular targeting awarded by University of California - Berkeley 2019 - 2023
- Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus awarded by National Institutes of Health 2018 - 2023
- Duke Resident Physician-Scientist Program - NIAID awarded by National Institutes of Health 2018 - 2023
- Direct Detection and Characterization of Blood Clots In Vivo awarded by University of California - Davis 2019 - 2023
- Project 3: RNA Aptamers as Probes and Regulators of Coagulation awarded by Children's Hospital of Philadelphia 2018 - 2023
- Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides awarded by Department of Defense 2020 - 2023
- Vaccine Adjuvant Discovery Program awarded by University of Montana 2019 - 2022
- Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
- Utilizing Nucleic Acid Binding Polymers to Ameliorate Inflammation-driven Metastatic Progression in Breast Cancer awarded by National Institutes of Health 2018 - 2021
- Targeting DAMP-induced inflammation to prevent metastasis awarded by Department of Defense 2016 - 2020
- Targeting DAMP-induced inflammation to prevent metastasis awarded by Department of Defense 2016 - 2020
- POEGMA Conjugation of Aptamers awarded by Gateway Bio, Inc. 2018 - 2020
- Genetics Training Grant awarded by National Institutes of Health 1979 - 2020
- Organization and Function of Cellular Structure awarded by National Institutes of Health 1975 - 2020
- Antithrombotic Aptamers and Antidotes awarded by National Institutes of Health 2000 - 2020
- Aptamer-based Detection and Binding of Peptide-MHC awarded by MD Anderson Cancer Center 2018 - 2019
- Duke-UNC Clinical Hematology and Transfusion Research Career Development Program awarded by National Institutes of Health 2006 - 2019
- DTMI-Center for Thrombotic and Hemostatic Disorders awarded by National Institutes of Health 2012 - 2019
- Neutralizing Antibody & AAV VIX Gene Therapy awarded by University of North Carolina - Chapel Hill 2017 - 2019
- Next-Generation Detection Reagents for Chromatin Immunoprecipitation awarded by EpiCypher, Inc. 2017 - 2018
- Studying Anticoagulant Synergy of Factor Xa Aptamer and Catalytic Site Inhibitors awarded by National Institutes of Health 2015 - 2018
- TRC-THD Administrative Coordinating Center (ACC) awarded by National Institutes of Health 2012 - 2017
- Aptamer Targeted Drug and Toxin Delivery to Prostate Cancer awarded by Department of Defense 2014 - 2016
- Targeting DNA Neutrophil Extracellular Traps in Sickle Cell Disease awarded by University of North Carolina - Chapel Hill 2013 - 2016
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1998 - 2016
- Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo awarded by Department of Defense 2012 - 2015
- RNA Therapeutics for Pancreatic Cancer awarded by National Institutes of Health 2011 - 2015
- Anticoagulant Synergy of Factor Xa Aptamer and Catalytic Site Inhibitors: Mechanistic and Translational Studies awarded by PhRMA Foundation 2015
- In Vivo Selection of Tumor-Specific RNA Binding Motifs awarded by National Institutes of Health 2011 - 2015
- Regulation of inflammatory responses by nucleic-acid binding polymers awarded by National Institutes of Health 2012 - 2014
- RNA aptamers as cell surface receptor agonists and siRNA delivery agents awarded by National Institutes of Health 2009 - 2014
- Nucleic Acid Binding Polymers as Anti-Inflammatory Agents awarded by National Institutes of Health 2011 - 2013
- CTSA UL awarded by National Institutes of Health 2006 - 2012
- In Vivo Selection of Aptamers Targeting Pancreatic Cancer awarded by National Institutes of Health 2011 - 2012
- Research Training In Neuro-Oncology awarded by National Institutes of Health 2005 - 2010
- Development and Analysis of Aptamer-Antidote Pairs awarded by National Institutes of Health 2000 - 2010
- Enhancement of Thrombolysis through Inhibition of PAI-1 and Antiplasmin awarded by National Institutes of Health 2007 - 2008
- E2F-Mediated Control of Vascular Growth and Remodeling awarded by National Institutes of Health 2003 - 2008
- The Angiopoietins in Vascular Maintenance and Remodeling awarded by National Institutes of Health 2002 - 2007
- Analysis of Group I and II Introns in Mammalian Cells awarded by National Institutes of Health 1995 - 2007
- Development of Oligonucleotide-based CTLA-4 Inhibitors. awarded by National Institutes of Health 2004 - 2006
- Disrupting Viral Gene with Group II Introns awarded by National Institutes of Health 2001 - 2006
- Rna Ligands: E2f Function and Cell Proliferation awarded by National Institutes of Health 1999 - 2003
- Developing RNA-Mimotopes Of Hiv Antigens awarded by National Institutes of Health 1998 - 2001
- Ribozyme Mediated Repair of Sickle B-Globin Transcripts awarded by National Institutes of Health 1996 - 2001
- Trans-splicing by a Group I Ribozyme in Mammalial Cells. awarded by National Institutes of Health 1998 - 2001
- Probing expressed genome organization with ribozymes awarded by National Institutes of Health 1997 - 2000
- Ribozyme-Mediated Repair Of Sickle B-Globin Transcripts awarded by National Institutes of Health 1996 - 1999
- Trans Splicing By A Group I Ribozyme In Mammalian Cells awarded by National Institutes of Health 1996 - 1999
- Trans-Splicing By A Group I Ribozyme In Mammalian Cells awarded by National Institutes of Health 1995 - 1999
- missing activity
- missing activity
- APTAMER BEACONS FOR EPIGENETIC HIGH-THROUGHOUT ASSAY DEVELOPMENT
-
External Relationships
- Basking Biosciences
- Dragon Therapeutics
- Eli Lilly & Co.
- Rznomics Inc
- Somalogic
- Upstream Therapeutics
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Song, X., H. Yu, C. Sullenger, B. P. Gray, A. Yan, L. Kelly, and B. Sullenger. “An Aptamer That Rapidly Internalizes into Cancer Cells Utilizes the Transferrin Receptor Pathway.” Cancers 15, no. 8 (April 1, 2023). https://doi.org/10.3390/cancers15082301.Full Text
-
Yu, Haixiang, James Frederiksen, and Bruce A. Sullenger. “Applications and future of aptamers that achieve rapid-onset anticoagulation.” Rna 29, no. 4 (April 2023): 455–62. https://doi.org/10.1261/rna.079503.122.Full Text Link to Item
-
Gray, Bethany Powell, Linsley Kelly, Kady-Ann Steen-Burrell, Juliana M. Layzer, Rachel E. Rempel, Shahid M. Nimjee, Brian C. Cooley, Alice F. Tarantal, and Bruce A. Sullenger. “Rapid molecular imaging of active thrombi in vivo using aptamer-antidote probes.” Mol Ther Nucleic Acids 31 (March 14, 2023): 440–51. https://doi.org/10.1016/j.omtn.2023.01.009.Full Text Link to Item
-
Puzzo, Francesco, Chuanling Zhang, Bethany Powell Gray, Feijie Zhang, Bruce A. Sullenger, and Mark A. Kay. “Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer.” Mol Ther Nucleic Acids 31 (March 14, 2023): 383–97. https://doi.org/10.1016/j.omtn.2023.01.007.Full Text Link to Item
-
Olson, Lyra B., Nicole I. Hunter, Rachel E. Rempel, Haixiang Yu, Diane M. Spencer, Cynthia Z. Sullenger, William S. Greene, et al. “Mixed-surface polyamidoamine polymer variants retain nucleic acid-scavenger ability with reduced toxicity.” Iscience 25, no. 12 (December 22, 2022): 105542. https://doi.org/10.1016/j.isci.2022.105542.Full Text Link to Item
-
Mohan, Aditya A., Lyra B. Olson, Ibtehaj A. Naqvi, Sarah A. Morrison, Bryan D. Kraft, Lingye Chen, Loretta G. Que, et al. “Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study.” Crit Care Explor 4, no. 12 (December 2022): e0799. https://doi.org/10.1097/CCE.0000000000000799.Full Text Link to Item
-
Shea, Susan M., Kimberly A. Thomas, Rassam M. G. Rassam, Emily P. Mihalko, Christina Daniel, Bruce A. Sullenger, Philip C. Spinella, and Shahid M. Nimjee. “Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion.” Pharmaceuticals (Basel) 15, no. 12 (November 22, 2022). https://doi.org/10.3390/ph15121450.Full Text Link to Item
-
Corey, Kristin M., Lyra B. Olson, Ibtehaj A. Naqvi, Sarah A. Morrison, Connor Davis, Shahid M. Nimjee, Loretta G. Que, et al. “Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study.” Anesthesiology 137, no. 1 (July 1, 2022): 67–78. https://doi.org/10.1097/ALN.0000000000004239.Full Text Link to Item
-
Olson, Lyra B., Nicole I. Hunter, Rachel E. Rempel, and Bruce A. Sullenger. “Targeting DAMPs with nucleic acid scavengers to treat lupus.” Transl Res 245 (July 2022): 30–40. https://doi.org/10.1016/j.trsl.2022.02.007.Full Text Link to Item
-
Chabata, Charlene V., James W. Frederiksen, Lyra B. Olson, Ibtehaj A. Naqvi, Sharon E. Hall, Ruwan Gunaratne, Bryan D. Kraft, Loretta G. Que, Lingye Chen, and Bruce A. Sullenger. “Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.” Nucleic Acid Ther 32, no. 3 (June 2022): 139–50. https://doi.org/10.1089/nat.2021.0077.Full Text Open Access Copy Link to Item
-
Naqvi, Ibtehaj, Nicholas Giroux, Lyra Olson, Sarah Ahn Morrison, Telmo Llanga, Tolu O. Akinade, Yuefei Zhu, et al. “DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists.” Biomaterials 283 (April 2022): 121393. https://doi.org/10.1016/j.biomaterials.2022.121393.Full Text Link to Item
-
Reed, Christopher R., Desiree Bonadonna, James C. Otto, Charles Griffin McDaniel, Charlene Vongai Chabata, Maragatha Kuchibhatla, James Frederiksen, et al. “Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO.” Mol Ther Nucleic Acids 27 (March 8, 2022): 524–34. https://doi.org/10.1016/j.omtn.2021.12.011.Full Text Link to Item
-
Ozer, Imran, George A. Pitoc, Juliana M. Layzer, Angelo Moreno, Lyra B. Olson, Kyle D. Layzer, Angus M. Hucknall, Bruce A. Sullenger, and Ashutosh Chilkoti. “PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response.” Adv Mater 34, no. 10 (March 2022): e2107852. https://doi.org/10.1002/adma.202107852.Full Text Link to Item
-
Kelly, Linsley, Lyra B. Olson, Rachel E. Rempel, Jeffrey I. Everitt, Dana Levine, Smita K. Nair, Mark E. Davis, and Bruce A. Sullenger. “β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes.” Mol Ther 30, no. 2 (February 2, 2022): 845–54. https://doi.org/10.1016/j.ymthe.2021.10.003.Full Text Link to Item
-
Soule, Erin E., Haixiang Yu, Lyra Olson, Ibtehaj Naqvi, Shekhar Kumar, Sriram Krishnaswamy, and Bruce A. Sullenger. “Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.” Cell Chemical Biology 29, no. 2 (February 2022): 215-225.e5. https://doi.org/10.1016/j.chembiol.2022.01.009.Full Text
-
Tu, Zhaoxu, Yiling Zhong, Hanze Hu, Dan Shao, Rainer Haag, Michael Schirner, Jaewoo Lee, Bruce Sullenger, and Kam W. Leong. “Design of therapeutic biomaterials to control inflammation.” Nat Rev Mater 7, no. 7 (2022): 557–74. https://doi.org/10.1038/s41578-022-00426-z.Full Text Link to Item
-
Eteshola, Elias O. U., Karenia Landa, Rachel E. Rempel, Ibtehaj A. Naqvi, E Shelley Hwang, Smita K. Nair, and Bruce A. Sullenger. “Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects.” Mol Ther Nucleic Acids 26 (December 3, 2021): 1–10. https://doi.org/10.1016/j.omtn.2021.06.016.Full Text Link to Item
-
Heggestad, Jacob T., Rhett J. Britton, David S. Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus M. Hucknall, Lyra B. Olson, et al. “Rapid test to assess the escape of SARS-CoV-2 variants of concern.” Sci Adv 7, no. 49 (December 3, 2021): eabl7682. https://doi.org/10.1126/sciadv.abl7682.Full Text Link to Item
-
Heggestad, Jacob T., David S. Kinnamon, Lyra B. Olson, Jason Liu, Garrett Kelly, Simone A. Wall, Solomon Oshabaheebwa, et al. “Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test.” Sci Adv 7, no. 26 (June 2021). https://doi.org/10.1126/sciadv.abg4901.Full Text Link to Item
-
Holl, Eda K., Victoria Frazier, Karenia Landa, David Boczkowski, Bruce Sullenger, and Smita K. Nair. “Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer.” Mol Ther 29, no. 5 (May 5, 2021): 1772–81. https://doi.org/10.1016/j.ymthe.2020.12.026.Full Text Link to Item
-
Olson, Lyra B., Ibtehaj A. Naqvi, Daniel J. Turner, Sarah A. Morrison, Bryan D. Kraft, Lingye Chen, Bruce A. Sullenger, Smita K. Nair, Loretta G. Que, and Jerrold H. Levy. “Key Pathogenic Factors in Coronavirus Disease 2019-Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report.” A a Pract 15, no. 4 (March 30, 2021): e01432. https://doi.org/10.1213/XAA.0000000000001432.Full Text Open Access Copy Link to Item
-
Hu, Jiabiao, Conrad P. Hodgkinson, Richard E. Pratt, JaeWoo Lee, Bruce A. Sullenger, and Victor J. Dzau. “Enhancing cardiac reprogramming via synthetic RNA oligonucleotides.” Mol Ther Nucleic Acids 23 (March 5, 2021): 55–62. https://doi.org/10.1016/j.omtn.2020.10.034.Full Text Link to Item
-
Zakeri, Amanda, Ashutosh P. Jadhav, Bruce A. Sullenger, and Shahid M. Nimjee. “Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist.” J Neurointerv Surg 13, no. 3 (March 2021): 202–6. https://doi.org/10.1136/neurintsurg-2020-016794.Full Text Link to Item
-
Stanfield, Brent A., Todd Purves, Scott Palmer, Bruce Sullenger, Karen Welty-Wolf, Krista Haines, Suresh Agarwal, and George Kasotakis. “IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages.” Plos One 16, no. 1 (2021): e0245169. https://doi.org/10.1371/journal.pone.0245169.Full Text Link to Item
-
Heggestad, Jacob T., David S. Kinnamon, Lyra B. Olson, Jason Liu, Garrett Kelly, Simone A. Wall, Cassio M. Fontes, et al. “Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test.” Medrxiv, November 7, 2020. https://doi.org/10.1101/2020.11.05.20226654.Full Text Link to Item
-
Powell Gray, Bethany, Xirui Song, David S. Hsu, Christina Kratschmer, Matthew Levy, Ashley P. Barry, and Bruce A. Sullenger. “An Aptamer for Broad Cancer Targeting and Therapy.” Cancers (Basel) 12, no. 11 (October 31, 2020). https://doi.org/10.3390/cancers12113217.Full Text Link to Item
-
Sullenger, Bruce A. “RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic.” Cell 181, no. 5 (May 28, 2020): 955–60. https://doi.org/10.1016/j.cell.2020.04.050.Full Text Link to Item
-
Kasotakis, George, Ekaterina Kintsurashvili, Manuel D. Galvan, Christopher Graham, J Todd Purves, Suresh Agarwal, David L. Corcoran, Bruce A. Sullenger, Scott M. Palmer, and Daniel G. Remick. “Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.” Shock 53, no. 3 (March 2020): 344–51. https://doi.org/10.1097/SHK.0000000000001372.Full Text Link to Item
-
Kasotakis, George, J Todd Purves, Suresh Agarwal, Bruce A. Sullenger, Ekaterina Kintsurashvili, Manuel D. Galvan, Christopher Graham, David L. Corcoran, Scott M. Palmer, and Daniel G. Remick. “Histone Deacetylase 7 in Murine Gram-Negative Acute Lung Injury.” Shock 53, no. 3 (March 2020): 375–77. https://doi.org/10.1097/SHK.0000000000001431.Full Text Link to Item
-
Gray, Bethany Powell, Martin D. Requena, Michael D. Nichols, and Bruce A. Sullenger. “Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.” Cell Chem Biol 27, no. 2 (February 20, 2020): 232-244.e7. https://doi.org/10.1016/j.chembiol.2019.12.004.Full Text Link to Item
-
Nimjee, Shahid M., and Bruce A. Sullenger. “Therapeutic Aptamers: Evolving to Find their Clinical Niche.” Curr Med Chem 27, no. 25 (2020): 4181–93. https://doi.org/10.2174/0929867326666191001125101.Full Text Link to Item
-
Nimjee, Shahid M., David Dornbos, George A. Pitoc, Debra G. Wheeler, Juliana M. Layzer, Nicholas Venetos, Allyson Huttinger, et al. “Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.” Mol Ther 27, no. 7 (July 3, 2019): 1228–41. https://doi.org/10.1016/j.ymthe.2019.03.016.Full Text Link to Item
-
Moreno, Angelo, George A. Pitoc, Nancy J. Ganson, Juliana M. Layzer, Michael S. Hershfield, Alice F. Tarantal, and Bruce A. Sullenger. “Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.” Cell Chem Biol 26, no. 5 (May 16, 2019): 634-644.e3. https://doi.org/10.1016/j.chembiol.2019.02.001.Full Text Link to Item
-
Darrabie, Marcus D., Jennifer Cheeseman, Alexander T. Limkakeng, Joseph Borawski, Bruce A. Sullenger, Eric A. Elster, Allan D. Kirk, and Jaewoo Lee. “Toll-like receptor activation as a biomarker in traumatically injured patients.” J Surg Res 231 (November 2018): 270–77. https://doi.org/10.1016/j.jss.2018.05.059.Full Text Open Access Copy Link to Item
-
Huttinger, Allyson L., Debra G. Wheeler, Surya Gnyawali, David Dornbos, Juliana M. Layzer, Nicholas Venetos, Spencer Talentino, et al. “Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury.” J Vis Exp, no. 139 (September 7, 2018). https://doi.org/10.3791/57981.Full Text Link to Item
-
Chabata, Charlene V., James W. Frederiksen, Bruce A. Sullenger, and Ruwan Gunaratne. “Emerging applications of aptamers for anticoagulation and hemostasis.” Curr Opin Hematol 25, no. 5 (September 2018): 382–88. https://doi.org/10.1097/MOH.0000000000000452.Full Text Link to Item
-
Gunaratne, Ruwan, Shekhar Kumar, James W. Frederiksen, Steven Stayrook, Jens L. Lohrmann, Kay Perry, Kristin M. Bompiani, et al. “Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.” Nat Biotechnol 36, no. 7 (August 2018): 606–13. https://doi.org/10.1038/nbt.4153.Full Text Link to Item
-
Powell Gray, Bethany, Linsley Kelly, Douglas P. Ahrens, Ashley P. Barry, Christina Kratschmer, Matthew Levy, and Bruce A. Sullenger. “Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.” Proc Natl Acad Sci U S A 115, no. 18 (May 1, 2018): 4761–66. https://doi.org/10.1073/pnas.1717705115.Full Text Link to Item
-
Naqvi, Ibtehaj, Ruwan Gunaratne, Jessica E. McDade, Angelo Moreno, Rachel E. Rempel, Douglas C. Rouse, Silvia Gabriela Herrera, et al. “Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.” Mol Ther 26, no. 4 (April 4, 2018): 1020–31. https://doi.org/10.1016/j.ymthe.2018.02.018.Full Text Link to Item
-
Steen Burrell, K. -. A., J. Layzer, and B. A. Sullenger. “A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.” J Thromb Haemost 15, no. 9 (September 2017): 1807–17. https://doi.org/10.1111/jth.13760.Full Text Link to Item
-
Woodruff, R. S., I. Ivanov, I. M. Verhamme, M. -. F. Sun, D. Gailani, and B. A. Sullenger. “Generation and characterization of aptamers targeting factor XIa.” Thromb Res 156 (August 2017): 134–41. https://doi.org/10.1016/j.thromres.2017.06.015.Full Text Link to Item
-
Lee, Jaewoo, Youngju Lee, Li Xu, Rebekah White, and Bruce A. Sullenger. “Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs.” Mol Ther 25, no. 6 (June 7, 2017): 1295–1305. https://doi.org/10.1016/j.ymthe.2017.03.014.Full Text Link to Item
-
Toulmé, J. J., P. H. Giangrande, G. Mayer, B. Suess, F. Ducongé, B. Sullenger, V. De Franciscis, F. Darfeuille, and E. Peyrin. “Aptamers in Bordeaux, 24–25 June 2016.” Pharmaceuticals 10, no. 1 (March 1, 2017). https://doi.org/10.3390/ph10010014.Full Text
-
Lee, Jaewoo, Jennifer G. Jackman, Jean Kwun, Miriam Manook, Angelo Moreno, Eric A. Elster, Allan D. Kirk, Kam W. Leong, and Bruce A. Sullenger. “Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis.” Biomaterials 120 (March 2017): 94–102. https://doi.org/10.1016/j.biomaterials.2016.12.024.Full Text Link to Item
-
Nimjee, Shahid M., Rebekah R. White, Richard C. Becker, and Bruce A. Sullenger. “Aptamers as Therapeutics.” Annu Rev Pharmacol Toxicol 57 (January 6, 2017): 61–79. https://doi.org/10.1146/annurev-pharmtox-010716-104558.Full Text Link to Item
-
Jackman, Jennifer G., Hemraj Juwarker, Luke P. Poveromo, Howard Levinson, Kam W. Leong, and Bruce A. Sullenger. “Polycationic Nanofibers for Nucleic Acid Scavenging.” Biomacromolecules 17, no. 11 (November 14, 2016): 3706–13. https://doi.org/10.1021/acs.biomac.6b01236.Full Text Link to Item
-
Lee, Jaewoo, Li Xu, Tyler M. Gibson, Charles A. Gersbach, and Bruce A. Sullenger. “Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.” Biochem Biophys Res Commun 478, no. 3 (September 23, 2016): 1484–90. https://doi.org/10.1016/j.bbrc.2016.08.159.Full Text Link to Item
-
Kahsai, Alem W., James W. Wisler, Jungmin Lee, Seungkirl Ahn, Thomas J. Cahill Iii, S Moses Dennison, Dean P. Staus, et al. “Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor.” Nat Chem Biol 12, no. 9 (September 2016): 709–16. https://doi.org/10.1038/nchembio.2126.Full Text Link to Item
-
Holl, Eda K., Kara L. Shumansky, Luke B. Borst, Angela D. Burnette, Christopher J. Sample, Elizabeth A. Ramsburg, and Bruce A. Sullenger. “Scavenging nucleic acid debris to combat autoimmunity and infectious disease.” Proc Natl Acad Sci U S A 113, no. 35 (August 30, 2016): 9728–33. https://doi.org/10.1073/pnas.1607011113.Full Text Link to Item
-
Sullenger, Bruce A., and Smita Nair. “From the RNA world to the clinic.” Science 352, no. 6292 (June 17, 2016): 1417–20. https://doi.org/10.1126/science.aad8709.Full Text Link to Item
-
Nimjee, Shahid M., Thomas J. Povsic, Bruce A. Sullenger, and Richard C. Becker. “Translation and Clinical Development of Antithrombotic Aptamers.” Nucleic Acid Ther 26, no. 3 (June 2016): 147–55. https://doi.org/10.1089/nat.2015.0581.Full Text Link to Item
-
Lee, Youngju, Johannes H. Urban, Li Xu, Bruce A. Sullenger, and Jaewoo Lee. “2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.” Nucleic Acid Ther 26, no. 3 (June 2016): 173–82. https://doi.org/10.1089/nat.2015.0575.Full Text Link to Item
-
Sullenger, Bruce A. “Aptamers Coming of Age at Twenty-Five.” Nucleic Acid Ther 26, no. 3 (June 2016): 119. https://doi.org/10.1089/nat.2016.29001.sul.Full Text Link to Item
-
Ganson, Nancy J., Thomas J. Povsic, Bruce A. Sullenger, John H. Alexander, Steven L. Zelenkofske, Jeffrey M. Sailstad, Christopher P. Rusconi, and Michael S. Hershfield. “Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.” J Allergy Clin Immunol 137, no. 5 (May 2016): 1610-1613.e7. https://doi.org/10.1016/j.jaci.2015.10.034.Full Text Link to Item
-
Mi, Jing, Partha Ray, Jenny Liu, Chien-Tsun Kuan, Jennifer Xu, David Hsu, Bruce A. Sullenger, Rebekah R. White, and Bryan M. Clary. “In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9.” Mol Ther Nucleic Acids 5, no. 4 (April 26, 2016): e315. https://doi.org/10.1038/mtna.2016.27.Full Text Link to Item
-
Soule, Erin E., Kristin M. Bompiani, Rebecca S. Woodruff, and Bruce A. Sullenger. “Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.” Nucleic Acid Ther 26, no. 1 (February 2016): 1–9. https://doi.org/10.1089/nat.2015.0565.Full Text Link to Item
-
Pratico, Elizabeth D., Bryan J. Feger, Michael J. Watson, Bruce A. Sullenger, Dawn E. Bowles, Carmelo A. Milano, and Smita K. Nair. “RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit(+) Cardiac Progenitor Cells.” Stem Cells Dev 24, no. 22 (November 15, 2015): 2622–33. https://doi.org/10.1089/scd.2015.0073.Full Text Link to Item
-
Woodruff, Rebecca S., and Bruce A. Sullenger. “Modulation of the Coagulation Cascade Using Aptamers.” Arterioscler Thromb Vasc Biol 35, no. 10 (October 2015): 2083–91. https://doi.org/10.1161/ATVBAHA.115.300131.Full Text Link to Item
-
Holl, Eda K., Jennifer E. Bond, Maria A. Selim, Tosan Ehanire, Bruce Sullenger, and Howard Levinson. “The nucleic acid scavenger polyamidoamine third-generation dendrimer inhibits fibroblast activation and granulation tissue contraction.” Plast Reconstr Surg 134, no. 3 (September 2014): 420e-433e. https://doi.org/10.1097/PRS.0000000000000471.Full Text Link to Item
-
Kotula, Jonathan W., Jinpeng Sun, Margie Li, Elizabeth D. Pratico, Mark P. Fereshteh, Douglas P. Ahrens, Bruce A. Sullenger, and Jeffrey J. Kovacs. “Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.” Plos One 9, no. 4 (2014): e93441. https://doi.org/10.1371/journal.pone.0093441.Full Text Link to Item
-
Ray, Partha, Bruce A. Sullenger, and Rebekah R. White. “Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.” Nucleic Acid Ther 23, no. 6 (December 2013): 435–42. https://doi.org/10.1089/nat.2013.0439.Full Text Link to Item
-
Woodruff, R. S., Y. Xu, J. Layzer, W. Wu, M. L. Ogletree, and B. A. Sullenger. “Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.” J Thromb Haemost 11, no. 7 (July 2013): 1364–73. https://doi.org/10.1111/jth.12302.Full Text Link to Item
-
Pratico, Elizabeth D., Bruce A. Sullenger, and Smita K. Nair. “Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.” Nucleic Acid Ther 23, no. 1 (February 2013): 35–43. https://doi.org/10.1089/nat.2012.0388.Full Text Link to Item
-
Holl, Eda K., Kara L. Shumansky, George Pitoc, Elizabeth Ramsburg, and Bruce A. Sullenger. “Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses.” Plos One 8, no. 7 (2013): e69413. https://doi.org/10.1371/journal.pone.0069413.Full Text Link to Item
-
Ray, Partha, Marcus A. Cheek, Mariam L. Sharaf, Na Li, Andrew D. Ellington, Bruce A. Sullenger, Barbara Ramsay Shaw, and Rebekah R. White. “Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.” Nucleic Acid Ther 22, no. 5 (October 2012): 295–305. https://doi.org/10.1089/nat.2012.0353.Full Text Link to Item
-
Jain, Shashank, George A. Pitoc, Eda K. Holl, Ying Zhang, Luke Borst, Kam W. Leong, Jaewoo Lee, and Bruce A. Sullenger. “Nucleic acid scavengers inhibit thrombosis without increasing bleeding.” Proc Natl Acad Sci U S A 109, no. 32 (August 7, 2012): 12938–43. https://doi.org/10.1073/pnas.1204928109.Full Text Link to Item
-
Bompiani, K. M., R. S. Woodruff, R. C. Becker, S. M. Nimjee, and B. A. Sullenger. “Antidote control of aptamer therapeutics: the road to a safer class of drug agents.” Curr Pharm Biotechnol 13, no. 10 (August 2012): 1924–34. https://doi.org/10.2174/138920112802273137.Full Text Link to Item
-
Rangnekar, Abhijit, Alex M. Zhang, Susan Shiyuan Li, Kristin M. Bompiani, Majken N. Hansen, Kurt V. Gothelf, Bruce A. Sullenger, and Thomas H. LaBean. “Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures.” Nanomedicine 8, no. 5 (July 2012): 673–81. https://doi.org/10.1016/j.nano.2011.08.011.Full Text Link to Item
-
Kotula, Jonathan W., Elizabeth D. Pratico, Xin Ming, Osamu Nakagawa, Rudolph L. Juliano, and Bruce A. Sullenger. “Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.” Nucleic Acid Ther 22, no. 3 (June 2012): 187–95. https://doi.org/10.1089/nat.2012.0347.Full Text Link to Item
-
Bompiani, K. M., D. M. Monroe, F. C. Church, and B. A. Sullenger. “A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.” J Thromb Haemost 10, no. 5 (May 2012): 870–80. https://doi.org/10.1111/j.1538-7836.2012.04679.x.Full Text Link to Item
-
Ray, Partha, Kristy L. Rialon-Guevara, Emanuela Veras, Bruce A. Sullenger, and Rebekah R. White. “Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.” J Clin Invest 122, no. 5 (May 2012): 1734–41. https://doi.org/10.1172/JCI62385.Full Text Link to Item
-
Sullenger, Bruce, Rebecca Woodruff, and Dougald M. Monroe. “Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.” J Biol Chem 287, no. 16 (April 13, 2012): 12779–86. https://doi.org/10.1074/jbc.M111.300772.Full Text Link to Item
-
Nimjee, Shahid M., Jens D. Lohrmann, Haichen Wang, David J. Snyder, Thomas J. Cummings, Richard C. Becker, Sabah Oney, and Bruce A. Sullenger. “Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.” Mol Ther 20, no. 2 (February 2012): 391–97. https://doi.org/10.1038/mt.2011.226.Full Text Link to Item
-
Pisetsky, David S., Jaewoo Lee, Kam W. Leong, and Bruce A. Sullenger. “Nucleic acid-binding polymers as anti-inflammatory agents: reducing the danger of nuclear attack.” Expert Rev Clin Immunol 8, no. 1 (January 2012): 1–3. https://doi.org/10.1586/eci.11.82.Full Text Link to Item
-
Stearns, Nancy A., Jaewoo Lee, Kam W. Leong, Bruce A. Sullenger, and David S. Pisetsky. “The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.” Plos One 7, no. 7 (2012): e40862. https://doi.org/10.1371/journal.pone.0040862.Full Text Link to Item
-
Wang, Jialiang, Bruce A. Sullenger, and Jeremy N. Rich. “Notch signaling in cancer stem cells.” Adv Exp Med Biol 727 (2012): 174–85. https://doi.org/10.1007/978-1-4614-0899-4_13.Full Text Link to Item
-
Brandal, Stephanie, Charlene M. Blake, Bruce A. Sullenger, and Yolanda M. Fortenberry. “Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.” Nucleic Acid Ther 21, no. 6 (December 2011): 373–81. https://doi.org/10.1089/nat.2011.0320.Full Text Link to Item
-
Lee, Jaewoo, Jang Wook Sohn, Ying Zhang, Kam W. Leong, David Pisetsky, and Bruce A. Sullenger. “Nucleic acid-binding polymers as anti-inflammatory agents.” Proc Natl Acad Sci U S A 108, no. 34 (August 23, 2011): 14055–60. https://doi.org/10.1073/pnas.1105777108.Full Text Link to Item
-
Burnette, Angela D., Shahid M. Nimjee, Milena Batchvarova, Rahima Zennadi, Marilyn J. Telen, Jun-Ichi Nishimura, and Bruce A. Sullenger. “RNA aptamer therapy for vaso-occlusion in sickle cell disease.” Nucleic Acid Ther 21, no. 4 (August 2011): 275–83. https://doi.org/10.1089/nat.2010.0270.Full Text Link to Item
-
Woodruff, Rebecca S., Bruce Sullenger, and Richard C. Becker. “The many faces of the contact pathway and their role in thrombosis.” J Thromb Thrombolysis 32, no. 1 (July 2011): 9–20. https://doi.org/10.1007/s11239-011-0578-5.Full Text Link to Item
-
Ray, Partha, Bruce A. Sullenger, and Rebekah R. White. “Abstract 2817: An RNA aptamer is a potential biomarker for pancreatic cancer.” Cancer Research 71, no. 8_Supplement (April 15, 2011): 2817–2817. https://doi.org/10.1158/1538-7445.am2011-2817.Full Text
-
Blake, Charlene M., Haichen Wang, Daniel T. Laskowitz, and Bruce A. Sullenger. “A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.” Oligonucleotides 21, no. 1 (February 2011): 11–19. https://doi.org/10.1089/oli.2010.0262.Full Text Link to Item
-
Povsic, Thomas J., Bruce A. Sullenger, Steven L. Zelenkofske, Christopher P. Rusconi, and Richard C. Becker. “Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.” J Cardiovasc Transl Res 3, no. 6 (December 2010): 704–16. https://doi.org/10.1007/s12265-010-9230-6.Full Text Link to Item
-
Huang, Leaf, Bruce Sullenger, and Rudy Juliano. “The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.” J Drug Target 18, no. 8 (September 2010): 567–74. https://doi.org/10.3109/10611861003734019.Full Text Link to Item
-
Woodruff, Becky, Bruce Sullenger, and Richard C. Becker. “Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?” Curr Cardiol Rep 12, no. 4 (July 2010): 315–20. https://doi.org/10.1007/s11886-010-0117-6.Full Text Link to Item
-
Becker, Richard C., Thomas Povsic, Mauricio G. Cohen, Christopher P. Rusconi, and Bruce Sullenger. “Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.” Thromb Haemost 103, no. 3 (March 2010): 586–95. https://doi.org/10.1160/TH09-10-0716.Full Text Link to Item
-
Buddai, Sai K., Juliana M. Layzer, Genmin Lu, Christopher P. Rusconi, Bruce A. Sullenger, Dougald M. Monroe, and Sriram Krishnaswamy. “An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase.” J Biol Chem 285, no. 8 (February 19, 2010): 5212–23. https://doi.org/10.1074/jbc.M109.049833.Full Text Link to Item
-
Mi, Jing, Yingmiao Liu, Zahid N. Rabbani, Zhongguang Yang, Johannes H. Urban, Bruce A. Sullenger, and Bryan M. Clary. “In vivo selection of tumor-targeting RNA motifs.” Nat Chem Biol 6, no. 1 (January 2010): 22–24. https://doi.org/10.1038/nchembio.277.Full Text Link to Item
-
Wang, Jialiang, Timothy P. Wakeman, Justin D. Lathia, Anita B. Hjelmeland, Xiao-Fan Wang, Rebekah R. White, Jeremy N. Rich, and Bruce A. Sullenger. “Notch promotes radioresistance of glioma stem cells.” Stem Cells 28, no. 1 (January 2010): 17–28. https://doi.org/10.1002/stem.261.Full Text Link to Item
-
Nimjee, Shahid M., Sabah Oney, Zoya Volovyk, Kristin M. Bompiani, Steve B. Long, Maureane Hoffman, and Bruce A. Sullenger. “Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.” Rna 15, no. 12 (December 2009): 2105–11. https://doi.org/10.1261/rna.1240109.Full Text Link to Item
-
Nimjee, S. M., and B. A. Sullenger. “Aptamers in the clinic.” Drugs of the Future 34, no. 11 (November 1, 2009): 897–901. https://doi.org/10.1358/dof.2009.34.11.1436007.Full Text
-
Oney, Sabah, Ruby T. S. Lam, Kristin M. Bompiani, Charlene M. Blake, George Quick, Jeremy D. Heidel, Joanna Yi-Ching Liu, et al. “Development of universal antidotes to control aptamer activity.” Nat Med 15, no. 10 (October 2009): 1224–28. https://doi.org/10.1038/nm.1990.Full Text Open Access Copy Link to Item
-
Zhou, Jing, Boonchoy Soontornworajit, Jacob Martin, Bruce A. Sullenger, Eli Gilboa, and Yong Wang. “A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling.” Macromol Biosci 9, no. 9 (September 9, 2009): 831–35. https://doi.org/10.1002/mabi.200900046.Full Text Link to Item
-
Becker, Richard C., Sabah Oney, Kristian C. D. Becker, and Bruce Sullenger. “Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.” Ann N Y Acad Sci 1175 (September 2009): 61–70. https://doi.org/10.1111/j.1749-6632.2009.05017.x.Full Text Link to Item
-
Blake, Charlene M., Bruce A. Sullenger, Daniel A. Lawrence, and Yolanda M. Fortenberry. “Antimetastatic potential of PAI-1-specific RNA aptamers.” Oligonucleotides 19, no. 2 (June 2009): 117–28. https://doi.org/10.1089/oli.2008.0177.Full Text Link to Item
-
Liu, Yingmiao, Chien-Tsun Kuan, Jing Mi, Xiuwu Zhang, Bryan M. Clary, Darell D. Bigner, and Bruce A. Sullenger. “Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.” Biol Chem 390, no. 2 (February 2009): 137–44. https://doi.org/10.1515/BC.2009.022.Full Text Link to Item
-
Mi, Zhiyong, Hongtao Guo, M Benjamin Russell, Yingmiao Liu, Bruce A. Sullenger, and Paul C. Kuo. “RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.” Mol Ther 17, no. 1 (January 2009): 153–61. https://doi.org/10.1038/mt.2008.235.Full Text Link to Item
-
Nimjee, S. M., and B. A. Sullenger. “Aptamers in the clinic.” Drugs of the Future 34, no. 11 (January 1, 2009): 897–901. https://doi.org/10.1358/dof.2009.034.11.1445907.Full Text
-
Liu, Yingmiao, Qi-An Sun, Qiang Chen, Tong H. Lee, Yangzhong Huang, William C. Wetsel, Gregory A. Michelotti, Bruce A. Sullenger, and Xiuwu Zhang. “Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking.” J Neurochem 108, no. 1 (January 2009): 147–57. https://doi.org/10.1111/j.1471-4159.2008.05748.x.Full Text Link to Item
-
Long, Stephen B., Meredith B. Long, Rebekah R. White, and Bruce A. Sullenger. “Crystal structure of an RNA aptamer bound to thrombin.” Rna 14, no. 12 (December 2008): 2504–12. https://doi.org/10.1261/rna.1239308.Full Text Link to Item
-
Lee, Jaewoo, Claudia M. Dollins, David Boczkowski, Bruce A. Sullenger, and Smita Nair. “Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses.” Immunology 125, no. 2 (October 2008): 229–40. https://doi.org/10.1111/j.1365-2567.2008.02833.x.Full Text Link to Item
-
Mi, J., B. A. Sullenger, and B. M. Clary. “Developing aptamers into tumor diagnostics and therapeutics.” Chinese Journal of Cancer Biotherapy 15, no. 4 (August 1, 2008): 301–4. https://doi.org/10.3872/j.issn.1007-385X.2008.04.001.Full Text
-
Dollins, Claudia M., Smita Nair, David Boczkowski, Jaewoo Lee, Juliana M. Layzer, Eli Gilboa, and Bruce A. Sullenger. “Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.” Chem Biol 15, no. 7 (July 21, 2008): 675–82. https://doi.org/10.1016/j.chembiol.2008.05.016.Full Text Link to Item
-
Viles, Kristi D., and Bruce A. Sullenger. “Proximity-dependent and proximity-independent trans-splicing in mammalian cells.” Rna 14, no. 6 (June 2008): 1081–94. https://doi.org/10.1261/rna.384808.Full Text Link to Item
-
Dollins, Claudia M., Smita Nair, and Bruce A. Sullenger. “Aptamers in immunotherapy.” Hum Gene Ther 19, no. 5 (May 2008): 443–50. https://doi.org/10.1089/hum.2008.045.Full Text Link to Item
-
Sarraf-Yazdi, Shiva, Jing Mi, Benjamin J. Moeller, Xilin Niu, Rebekah R. White, Christopher D. Kontos, Bruce A. Sullenger, Mark W. Dewhirst, and Bryan M. Clary. “Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.” J Surg Res 146, no. 1 (May 1, 2008): 16–23. https://doi.org/10.1016/j.jss.2007.04.028.Full Text Link to Item
-
Hong, Seung-Hee, Jin-Sook Jeong, Yoon-Jong Lee, Haeng-Im Jung, Kyoung-Sook Cho, Chang-Min Kim, Byung-Su Kwon, Bruce A. Sullenger, Seong-Wook Lee, and In-Hoo Kim. “In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.” Mol Ther 16, no. 1 (January 2008): 74–80. https://doi.org/10.1038/sj.mt.6300282.Full Text Link to Item
-
McNamara, James O., Despina Kolonias, Fernando Pastor, Robert S. Mittler, Lieping Chen, Paloma H. Giangrande, Bruce Sullenger, and Eli Gilboa. “Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.” J Clin Invest 118, no. 1 (January 2008): 376–86. https://doi.org/10.1172/JCI33365.Full Text Link to Item
-
Mi, Jing, Xiuwu Zhang, Zahid N. Rabbani, Yingmiao Liu, Srinevas K. Reddy, Zhen Su, Fawzia K. Salahuddin, et al. “RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin.” Mol Ther 16, no. 1 (January 2008): 66–73. https://doi.org/10.1038/sj.mt.6300320.Full Text Link to Item
-
White, Rebekah R., Julie A. Roy, Kristi D. Viles, Bruce A. Sullenger, and Christopher D. Kontos. “A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function.” Angiogenesis 11, no. 4 (2008): 395–401. https://doi.org/10.1007/s10456-008-9122-4.Full Text Link to Item
-
Becker, R. C., S. Oney, K. C. D. Becker, C. P. Rusconi, and B. Sullenger. “Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.” Hamostaseologie 27, no. 5 (December 2007): 378–82.Link to Item
-
Giangrande, Paloma H., JianXin Zhang, Alice Tanner, Andrea D. Eckhart, Rachel E. Rempel, Eran R. Andrechek, Juliana M. Layzer, et al. “Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.” Proc Natl Acad Sci U S A 104, no. 32 (August 7, 2007): 12988–93. https://doi.org/10.1073/pnas.0704754104.Full Text Link to Item
-
Mi, Jing, Xiuwu Zhang, Yingmiao Liu, Srinevas K. Reddy, Zahid N. Rabbani, Bruce A. Sullenger, and Bryan M. Clary. “NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis.” Biochem Biophys Res Commun 359, no. 3 (August 3, 2007): 475–80. https://doi.org/10.1016/j.bbrc.2007.05.125.Full Text Link to Item
-
Kierlin-Duncan, Monique N., and Bruce A. Sullenger. “Using 5'-PTMs to repair mutant beta-globin transcripts.” Rna 13, no. 8 (August 2007): 1317–27. https://doi.org/10.1261/rna.525607.Full Text Link to Item
-
Que-Gewirth, N. S., and B. A. Sullenger. “Gene therapy progress and prospects: RNA aptamers.” Gene Ther 14, no. 4 (February 2007): 283–91. https://doi.org/10.1038/sj.gt.3302900.Full Text Link to Item
-
Layzer, Juliana M., and Bruce A. Sullenger. “Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.” Oligonucleotides 17, no. 1 (2007): 1–11. https://doi.org/10.1089/oli.2006.0059.Full Text Link to Item
-
Oney, S., S. M. Nimjee, J. Layzer, N. Que-Gewirth, D. Ginsburg, R. C. Becker, G. Arepally, and B. A. Sullenger. “Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.” Oligonucleotides 17, no. 3 (2007): 265–74. https://doi.org/10.1089/oli.2007.0089.Full Text Link to Item
-
Nishimura, Jun-Ichi, Angela D. Burnette, Milena Batchvarova, Shahid M. Nimjee, Rahima Zennadi, Bruce A. Sullenger, and Marilyn J. Telen. “Blocking adhesion of sickle erythrocytes to endothelial alpha V beta 3 using RNA aptamer.” Blood 108, no. 11 (November 16, 2006): 206A-207A.Link to Item
-
Nimjee, Shahid M., J. R. Keys, G. A. Pitoc, G. Quick, C. P. Rusconi, and Bruce A. Sullenger. “A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.” Mol Ther 14, no. 3 (September 2006): 408–15. https://doi.org/10.1016/j.ymthe.2006.04.006.Full Text Link to Item
-
McNamara, James O., Eran R. Andrechek, Yong Wang, Kristi D. Viles, Rachel E. Rempel, Eli Gilboa, Bruce A. Sullenger, and Paloma H. Giangrande. “Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.” Nat Biotechnol 24, no. 8 (August 2006): 1005–15. https://doi.org/10.1038/nbt1223.Full Text Link to Item
-
Mi, Jing, Xiuwu Zhang, Zahid N. Rabbani, Yingmiao Liu, Zhen Su, Zeljko Vujaskovic, Christopher D. Kontos, Bruce A. Sullenger, and Bryan M. Clary. “H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity.” Nucleic Acids Res 34, no. 12 (2006): 3577–84. https://doi.org/10.1093/nar/gkl482.Full Text Link to Item
-
Mi, Jing, Xiuwu Zhang, Paloma H. Giangrande, James O. McNamara, Shahid M. Nimjee, Shiva Sarraf-Yazdi, Bruce A. Sullenger, and Bryan M. Clary. “Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.” Biochem Biophys Res Commun 338, no. 2 (December 16, 2005): 956–63. https://doi.org/10.1016/j.bbrc.2005.10.043.Full Text Link to Item
-
Becker, Richard C., Christopher Rusconi, and Bruce Sullenger. “Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application.” Thromb Haemost 93, no. 6 (June 2005): 1014–20. https://doi.org/10.1160/TH04-12-0790.Full Text Link to Item
-
Jones, John Patrick, Monique N. Kierlin, Robert G. Coon, Jiri Perutka, Alan M. Lambowitz, and Bruce A. Sullenger. “Retargeting mobile group II introns to repair mutant genes.” Mol Ther 11, no. 5 (May 2005): 687–94. https://doi.org/10.1016/j.ymthe.2005.01.014.Full Text Link to Item
-
Nimjee, Shahid M., Christopher P. Rusconi, Robert A. Harrington, and Bruce A. Sullenger. “The potential of aptamers as anticoagulants.” Trends Cardiovasc Med 15, no. 1 (January 2005): 41–45. https://doi.org/10.1016/j.tcm.2005.01.002.Full Text Link to Item
-
Nimjee, Shahid M., Christopher P. Rusconi, and Bruce A. Sullenger. “Aptamers: an emerging class of therapeutics.” Annu Rev Med 56 (2005): 555–83. https://doi.org/10.1146/annurev.med.56.062904.144915.Full Text Link to Item
-
Sullenger, Bruce A. “Riboswitches--to kill or save the messenger.” N Engl J Med 351, no. 26 (December 23, 2004): 2759–60. https://doi.org/10.1056/NEJMcibr043522.Full Text Link to Item
-
Rusconi, Christopher P., Joseph D. Roberts, George A. Pitoc, Shahid M. Nimjee, Rebekah R. White, George Quick, Elizabeth Scardino, William P. Fay, and Bruce A. Sullenger. “Antidote-mediated control of an anticoagulant aptamer in vivo.” Nat Biotechnol 22, no. 11 (November 2004): 1423–28. https://doi.org/10.1038/nbt1023.Full Text Link to Item
-
Potti, Anil, Christopher P. Rusconi, Bruce A. Sullenger, and Thomas L. Ortel. “Regulatable aptamers in medicine: focus on antithrombotic strategies.” Expert Opin Biol Ther 4, no. 10 (October 2004): 1641–47. https://doi.org/10.1517/14712598.4.10.1641.Full Text Link to Item
-
Shin, Kyung-Sook, Bruce A. Sullenger, and Seong-Wook Lee. “Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.” Mol Ther 10, no. 2 (August 2004): 365–72. https://doi.org/10.1016/j.ymthe.2004.05.007.Full Text Link to Item
-
Jeter, Martha L., Linda V. Ly, Yolanda M. Fortenberry, Herbert C. Whinna, Rebekah R. White, Christopher P. Rusconi, Bruce A. Sullenger, and Frank C. Church. “RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins.” Febs Lett 568, no. 1–3 (June 18, 2004): 10–14. https://doi.org/10.1016/j.febslet.2004.04.087.Full Text Link to Item
-
Layzer, Juliana M., Anton P. McCaffrey, Alice K. Tanner, Zan Huang, Mark A. Kay, and Bruce A. Sullenger. “In vivo activity of nuclease-resistant siRNAs.” Rna 10, no. 5 (May 2004): 766–71. https://doi.org/10.1261/rna.5239604.Full Text Link to Item
-
Santulli-Marotto, Sandra, Smita K. Nair, Chris Rusconi, Bruce Sullenger, and Eli Gilboa. “Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.” Cancer Res 63, no. 21 (November 1, 2003): 7483–89.Link to Item
-
Byun, Jonghoe, Ning Lan, Meredith Long, and Bruce A. Sullenger. “Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.” Rna 9, no. 10 (October 2003): 1254–63. https://doi.org/10.1261/rna.5450203.Full Text Link to Item
-
White, Rebekah R., Siqing Shan, Christopher P. Rusconi, Geetha Shetty, Mark W. Dewhirst, Christopher D. Kontos, and Bruce A. Sullenger. “Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.” Proc Natl Acad Sci U S A 100, no. 9 (April 29, 2003): 5028–33. https://doi.org/10.1073/pnas.0831159100.Full Text Link to Item
-
Sullenger, B. A., R. R. White, and C. P. Rusconi. “Therapeutic aptamers and antidotes: a novel approach to safer drug design.” Ernst Schering Res Found Workshop, no. 43 (2003): 217–23. https://doi.org/10.1007/978-3-662-05352-2_13.Full Text Link to Item
-
Rogers, Christopher S., Carlos G. Vanoye, Bruce A. Sullenger, and Alfred L. George. “Functional repair of a mutant chloride channel using a trans-splicing ribozyme.” J Clin Invest 110, no. 12 (December 2002): 1783–89. https://doi.org/10.1172/JCI16481.Full Text Link to Item
-
Rusconi, Christopher P., Elizabeth Scardino, Juliana Layzer, George A. Pitoc, Thomas L. Ortel, Dougald Monroe, and Bruce A. Sullenger. “RNA aptamers as reversible antagonists of coagulation factor IXa.” Nature 419, no. 6902 (September 5, 2002): 90–94. https://doi.org/10.1038/nature00963.Full Text Link to Item
-
Sullenger, Bruce A., and Eli Gilboa. “Emerging clinical applications of RNA.” Nature 418, no. 6894 (July 11, 2002): 252–58. https://doi.org/10.1038/418252a.Full Text Link to Item
-
Martell, Robert E., Joseph R. Nevins, and Bruce A. Sullenger. “Optimizing aptamer activity for gene therapy applications using expression cassette SELEX.” Mol Ther 6, no. 1 (July 2002): 30–34. https://doi.org/10.1006/mthe.2002.0624.Full Text Link to Item
-
White, R., C. Rusconi, E. Scardino, A. Wolberg, J. Lawson, M. Hoffman, and B. Sullenger. “Generation of species cross-reactive aptamers using "toggle" SELEX.” Mol Ther 4, no. 6 (December 2001): 567–73. https://doi.org/10.1006/mthe.2001.0495.Full Text Link to Item
-
Watanabe, T., and B. A. Sullenger. “RNA repair: a novel approach to gene therapy.” Adv Drug Deliv Rev 44, no. 2–3 (November 15, 2000): 109–18. https://doi.org/10.1016/s0169-409x(00)00089-2.Full Text Link to Item
-
Rusconi, C. P., A. Yeh, H. K. Lyerly, J. H. Lawson, and B. A. Sullenger. “Blocking the initiation of coagulation by RNA aptamers to factor VIIa.” Thromb Haemost 84, no. 5 (November 2000): 841–48.Link to Item
-
White, R. R., B. A. Sullenger, and C. P. Rusconi. “Developing aptamers into therapeutics.” J Clin Invest 106, no. 8 (October 2000): 929–34. https://doi.org/10.1172/JCI11325.Full Text Link to Item
-
Sullenger, B. A. “Series introduction: emerging clinical applications of nucleic acids.” J Clin Invest 106, no. 8 (October 2000): 921–22. https://doi.org/10.1172/JCI11343.Full Text Link to Item
-
Lan, N., B. L. Rooney, S. W. Lee, R. P. Howrey, C. A. Smith, and B. A. Sullenger. “Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA.” Mol Ther 2, no. 3 (September 2000): 245–55. https://doi.org/10.1006/mthe.2000.0125.Full Text Link to Item
-
Guo, H., M. Karberg, M. Long, J. P. Jones, B. Sullenger, and A. M. Lambowitz. “Group II introns designed to insert into therapeutically relevant DNA target sites in human cells.” Science 289, no. 5478 (July 21, 2000): 452–57. https://doi.org/10.1126/science.289.5478.452.Full Text Link to Item
-
Watanabe, T., and B. A. Sullenger. “Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.” Proc Natl Acad Sci U S A 97, no. 15 (July 18, 2000): 8490–94. https://doi.org/10.1073/pnas.150104097.Full Text Link to Item
-
Howrey, R. P., M. El-Alfondi, K. L. Phillips, L. Wilson, B. Rooney, N. Lan, B. Sullenger, and C. Smith. “An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies.” Gene Ther 7, no. 3 (February 2000): 215–23. https://doi.org/10.1038/sj.gt.3301064.Full Text Link to Item
-
Long, M. B., and B. A. Sullenger. “Evaluating group I intron catalytic efficiency in mammalian cells.” Mol Cell Biol 19, no. 10 (October 1999): 6479–87. https://doi.org/10.1128/MCB.19.10.6479.Full Text Link to Item
-
Sullenger, B. A. “RNA repair as a novel approach to genetic therapy.” Gene Ther 6, no. 4 (April 1999): 461–62. https://doi.org/10.1038/sj.gt.3300903.Full Text Link to Item
-
Zarrinkar, P. P., and B. A. Sullenger. “Optimizing the substrate specificity of a group I intron ribozyme.” Biochemistry 38, no. 11 (March 16, 1999): 3426–32. https://doi.org/10.1021/bi982688m.Full Text Link to Item
-
Zarrinkar, P. P., and B. A. Sullenger. “Probing the interplay between the two steps of group I intron splicing: competition of exogenous guanosine with omega G.” Biochemistry 37, no. 51 (December 22, 1998): 18056–63. https://doi.org/10.1021/bi982193x.Full Text Link to Item
-
Lan, N., R. P. Howrey, S. W. Lee, C. A. Smith, and B. A. Sullenger. “Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors.” Science 280, no. 5369 (June 5, 1998): 1593–96. https://doi.org/10.1126/science.280.5369.1593.Full Text Link to Item
-
Jones, J. T., and B. A. Sullenger. “Evaluating and enhancing ribozyme reaction efficiency in mammalian cells.” Nat Biotechnol 15, no. 9 (September 1997): 902–5. https://doi.org/10.1038/nbt0997-902.Full Text Link to Item
-
Lee, S. W., and B. A. Sullenger. “Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies.” Nat Biotechnol 15, no. 1 (January 1997): 41–45. https://doi.org/10.1038/nbt0197-41.Full Text Link to Item
-
Jones, J. T., S. W. Lee, and B. A. Sullenger. “Trans-splicing reactions by ribozymes.” Methods Mol Biol 74 (1997): 341–48. https://doi.org/10.1385/0-89603-389-9:341.Full Text Link to Item
-
Ishizaki, J., J. R. Nevins, and B. A. Sullenger. “Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.” Nat Med 2, no. 12 (December 1996): 1386–89. https://doi.org/10.1038/nm1296-1386.Full Text Link to Item
-
Sullenger, B. A. “Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors.” Cytokines Mol Ther 2, no. 3 (September 1996): 201–5.Link to Item
-
Lee, S. W., and B. A. Sullenger. “Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes.” J Exp Med 184, no. 2 (August 1, 1996): 315–24. https://doi.org/10.1084/jem.184.2.315.Full Text Link to Item
-
Jones, J. T., S. W. Lee, and B. A. Sullenger. “Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells.” Nat Med 2, no. 6 (June 1996): 643–48. https://doi.org/10.1038/nm0696-643.Full Text Link to Item
-
Sullenger, B. A. “Revising messages traveling along the cellular information superhighway.” Chem Biol 2, no. 5 (May 1995): 249–53. https://doi.org/10.1016/1074-5521(95)90043-8.Full Text Link to Item
-
Doudna, J. A., T. R. Cech, and B. A. Sullenger. “Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor.” Proc Natl Acad Sci U S A 92, no. 6 (March 14, 1995): 2355–59. https://doi.org/10.1073/pnas.92.6.2355.Full Text Link to Item
-
CECH, T. R., S. A. STROBEL, and B. A. SULLENGER. “STRUCTURE AND MECHANISM OF A GROUP-I RIBOZYME AND APPLICATIONS IN BIOTECHNOLOGY.” Protein Engineering 8 (January 1, 1995): 16–16.Link to Item
-
Smith, C., and B. A. Sullenger. “AIDS and HIV infection.” Mol Cell Biol Hum Dis Ser 5 (1995): 195–236. https://doi.org/10.1007/978-94-011-0547-7_11.Full Text Link to Item
-
Campbell, T. B., and B. A. Sullenger. “Alternative approaches for the application of ribozymes as gene therapies for retroviral infections.” Adv Pharmacol 33 (1995): 143–78. https://doi.org/10.1016/s1054-3589(08)60668-7.Full Text Link to Item
-
Sullenger, B. A. “Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors.” Appl Biochem Biotechnol 54, no. 1–3 (1995): 57–61. https://doi.org/10.1007/BF02787911.Full Text Link to Item
-
Sullenger, B. A., and T. R. Cech. “Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing.” Nature 371, no. 6498 (October 13, 1994): 619–22. https://doi.org/10.1038/371619a0.Full Text Link to Item
-
Sullenger, B. A., and T. R. Cech. “Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA.” Science 262, no. 5139 (December 3, 1993): 1566–69. https://doi.org/10.1126/science.8248806.Full Text Link to Item
-
Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers, and E. Gilboa. “Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.” New Biol 4, no. 1 (January 1992): 66–74.Link to Item
-
Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. “Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation.” J Virol 65, no. 12 (December 1991): 6811–16. https://doi.org/10.1128/JVI.65.12.6811-6816.1991.Full Text Link to Item
-
Sullenger, B. A., T. C. Lee, C. A. Smith, G. E. Ungers, and E. Gilboa. “Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.” Mol Cell Biol 10, no. 12 (December 1990): 6512–23. https://doi.org/10.1128/mcb.10.12.6512-6523.1990.Full Text Link to Item
-
Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. “Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.” Cell 63, no. 3 (November 2, 1990): 601–8. https://doi.org/10.1016/0092-8674(90)90455-n.Full Text Link to Item
-
Hantzopoulos, P. A., B. A. Sullenger, G. Ungers, and E. Gilboa. “Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector.” Proc Natl Acad Sci U S A 86, no. 10 (May 1989): 3519–23. https://doi.org/10.1073/pnas.86.10.3519.Full Text Link to Item
-
Eteshola, Elias O. U., Karenia Landa, Rachel E. Rempel, Ibtehaj A. Naqvi, E Shelley Hwang, Smita K. Nair, and Bruce A. Sullenger. “Nucleic-Acid Scavengers Mitigate Breast Cancer Induced Inflammation, Invasion, and Metastasis,” n.d.
-
-
Book Sections
-
Yu, H., J. Frederiksen, and B. A. Sullenger. “Aptamer-based protein inhibitors.” In RNA Therapeutics: The Evolving Landscape of RNA Therapeutics, 89–120, 2022. https://doi.org/10.1016/B978-0-12-821595-1.00008-7.Full Text
-
Milich, L., and B. A. Sullenger. “Ribozymes as Tools for the Gene Therapist.” In Concepts in Gene Therapy, 197–229, 2020. https://doi.org/10.1515/9783110808636-012.Full Text
-
Blake, C. M., S. Oney, S. M. Nimjee, and B. A. Sullenger. “Aptamers and siRNAs in cardiovascular disease.” In RNA Technologies in Cardiovascular Medicine and Research, 255–87, 2008. https://doi.org/10.1007/978-3-540-78709-9_13.Full Text
-
Nimjee, S. M., C. P. Rusconi, and B. A. Sullenger. “Aptamers to Proteins.” In The Aptamer Handbook: Functional Oligonucleotides and Their Applications, 131–66, 2006. https://doi.org/10.1002/3527608192.ch6.Full Text
-
-
Other Articles
-
Sullenger, Bruce, and Fintan Steele. “Something old, something new.” Nucleic Acid Ther, December 2011. https://doi.org/10.1089/nat.2011.1504.Full Text Link to Item
-
-
Conference Papers
-
Olson, Lyra B., Ibtehaj A. Naqvi, L. I. N. G. Y. E. CHEN, Loretta G. Que, BRYAN D. KRAFT, Smita K. Nair, Shahid M. Nimjee, and Bruce A. Sullenger. “Abstract P102: Elevated Von Willebrand Factor in Patients Presenting With Large-Vessel Occlusion Stroke as First Symptom of COVID-19 Mirrors Levels in Patients With COVID-19 Requiring ICU-Level Care.” In Stroke, Vol. 52. Ovid Technologies (Wolters Kluwer Health), 2021. https://doi.org/10.1161/str.52.suppl_1.p102.Full Text
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology Biomarkers & Prevention, Vol. 29, 2020.Link to Item
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Abstract B006: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology, Biomarkers &Amp; Prevention, 29:B006–B006. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7755.disp18-b006.Full Text
-
Eteshola, Elias O. U., Karenia Landa, E Shelley Hwang, Angelo Moreno, Smita K. Nair, and Bruce A. Sullenger. “Blocking proinvasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NAS).” In Cancer Immunology Research, 8:76–76. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Sullenger, Bruce A. “Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents.” In Blood, Vol. 134. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-121056.Full Text
-
Eteshola, Elias O., Ibtehaj A. Naqvi, Ruwan Gunaratne, Angelo Moreno, Smita K. Nair, and Bruce A. Sullenger. “Abstract 4515: Utilizing nucleic-acid scavengers (NASs) to inhibit proinflammatory and proinvasive signaling in triple-negative breast cancer.” In Cancer Research, 79:4515–4515. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.am2019-4515.Full Text
-
Chabata, Charlene V., Ruwan Gunaratne, James W. Frederiksen, and Bruce A. Sullenger. “Exploring Novel Aptamer-Heparin Combinations to Improve Anticoagulation Therapy in Cardiopulmonary Bypass.” In Molecular Therapy, 27:364–65. CELL PRESS, 2019.Link to Item
-
Landa, K., E. Holl, V. N. Frazier, B. A. Sullenger, E. Hwang, and S. Nair. “Targeting DAMPs-Induced Inflammation in Breast Cancer.” In Annals of Surgical Oncology, 26:S71–S71. SPRINGER, 2019.Link to Item
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology Biomarkers & Prevention, 27:46–46. AMER ASSOC CANCER RESEARCH, 2018.Link to Item
-
LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells.” In Cancer Epidemiology Biomarkers & Prevention, 27:148–148. AMER ASSOC CANCER RESEARCH, 2018.Link to Item
-
Dornbos, David L., Debra G. Wheeler, Matthew E. Joseph, George A. Pitoc, Julie M. Layzer, Allyson Huttinger, Spencer Talentino, et al. “Translating Thrombolytic Efficacy of Von Willebrand Factor Aptamer Inhibition From a Small to Large Animal Model of Carotid Occlusion.” In Circulation, Vol. 136. LIPPINCOTT WILLIAMS & WILKINS, 2017.Link to Item
-
Kim, Jina, Ibtehaj Naqvi, Uttara P. Nag, Harold J. Leraas, James C. Otto, Alexandra J. Borst, Kevin D. Hill, Gregory A. Fleming, Bruce A. Sullenger, and Elisabeth T. Tracy. “Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.Link to Item
-
Gunaratne, Ruwan, James Frederiksen, Nabil K. Thalji, Michelle D. Ho, Gowthami M. Arepally, Rodney M. Camire, and Bruce A. Sullenger. “RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit.” In Blood, 128:3823–3823. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3823.3823.Full Text
-
Plautz, William E., Juliana Layzer, Bruce A. Sullenger, and Rinku Majumder. “Aptamer Mediated Inhibition of Protein S.” In Blood, 128:4946–4946. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.4946.4946.Full Text
-
Darrabie, Marcus D., Jaewoo Lee, Jennifer Cheeseman, Alexander T. Limkakeng, Steven N. Vaslef, Bruce A. Sullenger, and Allan D. Kirk. “Toll-Like Receptor Signaling as a Prognostic Tool in Trauma Patients.” In Journal of the American College of Surgeons, 223:S159–60. Ovid Technologies (Wolters Kluwer Health), 2016. https://doi.org/10.1016/j.jamcollsurg.2016.06.346.Full Text
-
Freedman, Jennifer A., Timothy J. Robinson, Bonnie LaCroix, Brendon M. Patierno, Daniel J. George, Bruce A. Sullenger, and Steven R. Patierno. “Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent.” In Cancer Epidemiology, Biomarkers &Amp; Prevention, 25:B18–B18. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7755.disp15-b18.Full Text
-
Soule, E., S. Krishnaswamy, and B. A. Sullenger. “Development and characterization of an RNA aptamer targeting FV/FVA.” In Journal of Thrombosis and Haemostasis, 13:54–55. WILEY-BLACKWELL, 2015.Link to Item
-
Gray, Bethany Powell, Linsley Kelly, Matthew Levy, and Bruce A. Sullenger. “A Novel Aptamer Targeting Agent for Prostate Cancer.” In Molecular Therapy, 23:S28–29. NATURE PUBLISHING GROUP, 2015.Link to Item
-
Pratico, Elizabeth D., Smita K. Nair, and Bruce A. Sullenger. “66. Identification and Characterization of a B Cell Aptamer That Targets Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Myelogenous Leukemia (CML).” In Molecular Therapy, 23:S29–S29. Elsevier BV, 2015. https://doi.org/10.1016/s1525-0016(16)33671-1.Full Text
-
Gray, Bethany Powell, Linsley Kelly, Matthew Levy, and Bruce A. Sullenger. “A novel aptamer targeting agent for prostate cancer.” In Cancer Research, Vol. 75, 2015. https://doi.org/10.1158/1538-7445.AM2015-5523.Full Text Link to Item
-
Kumar, Shekhar, Bruce A. Sullenger, Steven Stayrook, and Sriram Krishnaswamy. “X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Lewis, Deborah A., Shahid M. Nimjee, George A. Pitoc, Shoeb Khan, Richard C. Becker, Bruce A. Sullenger, and Thomas L. Ortel. “Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Juwarker, Hemraj A., Eda K. Holl, Yeh-Hsing Lao, Kam W. Leong, and Bruce A. Sullenger. “Nucleic-Acid Binding Polymers as Anti-Inflammatory Agents.” In Molecular Therapy, 22:S4–5. NATURE PUBLISHING GROUP, 2014.Link to Item
-
Gunaratne, Ruwan, James Frederiksen, Jens Lohrmann, Kristin M. Bompiani, Rebecca Smock-Woodruff, and Bruce A. Sullenger. “Aptamers Against Factor Xa or Thrombin Synergize With Catalytic Site Inhibitors of FXa or Thrombin, Respectively, to Effectively Anticoagulate Blood in an Ex Vivo Oxygenator Circuit.” In Arteriosclerosis Thrombosis and Vascular Biology, Vol. 34, 2014.Link to Item
-
Lee, Jaewoo, Youngju Lee, and Bruce A. Sullenger. “Development of immunocytotoxic RNA therapeutics for human melanoma.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-2639.Full Text Link to Item
-
Frederiksen, J. W., J. Lohrmann, K. M. Bompiani, R. B. S. Smock-Woodruff, R. B. A. Gunaratne, and B. A. Sullenger. “Aptamer inhibition of an exosite of Factor (F)Xa or thrombin synergizes with non-aptamer inhibition of the catalytic site of FXa or thrombin, respectively.” In Journal of Thrombosis and Haemostasis, 11:123–24. WILEY-BLACKWELL, 2013.Link to Item
-
Ray, Partha, Bruce A. Sullenger, and Rebekah R. White. “AN RNA APTAMER IS A POTENTIAL BIOMARKER FOR PANCREATIC CANCER.” In Nucleic Acid Therapeutics, 21:A40–41. MARY ANN LIEBERT INC, 2011.Link to Item
-
Bompiani, K. M., J. Lorhmann, J. Frederiksen, and B. A. Sullenger. “Individual anticoagulant aptamers uniquely impair thrombin generation and have a synergistic effect when used in combination.” In Journal of Thrombosis and Haemostasis, 9:278–278. WILEY-BLACKWELL, 2011.Link to Item
-
Lee, Jaewoo, and Bruce A. Sullenger. “POLYMERS AS MOLECULAR SCAVENGERS TO NEUTRALIZE PRO-INFLAMMATORY NUCLEIC ACIDS.” In Inflammation Research, 59:S293–S293. BIRKHAUSER VERLAG AG, 2010.Link to Item
-
Fortenberry, Yolanda, Charlene M. Blake, and Bruce A. Sullenger. “Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.” In Blood, 114:840–840. AMER SOC HEMATOLOGY, 2009.Link to Item
-
Lam, Ruby T. S., Sabah Oney, Bruce A. Sullenger, and Kam W. Leong. “Oral delivery of RNA aptamer as reversible antagonist of coagulation factor IXa.” In Abstracts of Papers of the American Chemical Society, 237:517–517. AMER CHEMICAL SOC, 2009.Link to Item
-
Nishimura, Jun-ichi, Angela D. Burnette, Sabah Oney, Milena Batchvarova, Martha Delahunty, Rahima Zennadi, Bruce A. Sullenger, and Marilyn J. Telen. “Blocking adhesion of sickle erythrocytes to endothelial P-selectin using an RNAaptamer.” In Blood, 110:51A-51A. AMER SOC HEMATOLOGY, 2007.Link to Item
-
Lange, Fellery de, Shahid M. Nimjee, George A. Pitoc, Hilary P. Grocott, G. B. Mackensen, and Bruce A. Sullenger. “Aptamer to factor IXa and matched antidote improve cardiac function after cardiopulmonary bypass in rats; an alternative to heparin and protamine.” In Circulation, 114:104–104. LIPPINCOTT WILLIAMS & WILKINS, 2006.Link to Item
-
Catron, Daniel J., Paloma H. Giangrande, and Bruce A. Sullenger. “1028. Use of Antisense Oligonucleotides To Restore Activity in Mutant p53.” In Molecular Therapy, 13:S395–S395. Elsevier BV, 2006. https://doi.org/10.1016/j.ymthe.2006.08.1123.Full Text
-
Giangrande, Paloma H., James O. McNamara, Eran Andrecheck, Eli Gilboa, and Bruce A. Sullenger. “83. Cell_Type Specific Delivery of siRNAs with Aptamer_siRNA Chimeras.” In Molecular Therapy, 13:S35–S35. Elsevier BV, 2006. https://doi.org/10.1016/j.ymthe.2006.08.101.Full Text
-
Nishimura, Jun-ichi, Shahid M. Nimjee, Haixiang Jiang, Thad A. Howard, George A. Pitoc, Christopher P. Rusconi, Mitsuhiro Omine, et al. “Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8.” In Blood, 106:186–186. American Society of Hematology, 2005. https://doi.org/10.1182/blood.v106.11.186.186.Full Text
-
Nishimura, Jun-ichi, Shahid Nimjee, Haixiang Jiang, Tatsuya Kawaguchi, Hideki Nakakuma, Mitsuhiro Omine, Michael M. Frank, Russell E. Ware, and Bruce A. Sullenger. “Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.” In Blood, 104:2824–2824. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.2824.2824.Full Text
-
Catron, D. J., T. Watanabe, K. S. Shin, E. M. Toloza, S. W. Lee, and B. A. Sullenger. “Group I intron-mediated trans-splicing revision of mutant p53 RNA transcripts.” In Molecular Therapy, 9:S231–S231. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2004.Link to Item
-
Nimjee, S. M., J. R. Keys, G. A. Pitoc, G. Quick, C. P. Rusconi, and B. A. Sullenger. “Aptamer to factor IXa and its matched antidote in cardiopulmonary bypass: An alternative to heparin and protamine.” In Arteriosclerosis Thrombosis and Vascular Biology, 24:E7–E7. LIPPINCOTT WILLIAMS & WILKINS, 2004.Link to Item
-
Nishimura, J., S. M. Nimjee, H. X. Jiang, G. Pitoc, T. A. Howard, C. P. Rusconi, M. Omine, M. M. Frank, B. A. Sullenger, and R. E. Ware. “Complement-mediated hemolysis of erythrocytes is blocked by RNA aptamers to complement components C5 and C8.” In Blood, 102:510A-510A. AMER SOC HEMATOLOGY, 2003.Link to Item
-
Rusconi, C. P., J. D. Roberts, G. A. Pitoc, S. M. Nimjee, R. R. White, W. P. Fay, and B. A. Sullenger. “In Vivo applications of an antidote-controlled anticoagulant targeting coagulation factor IXa.” In Circulation, 108:138–138. LIPPINCOTT WILLIAMS & WILKINS, 2003.Link to Item
-
Jeter, M. L., R. R. White, B. A. Sullenger, C. P. Rusconi, and F. C. Church. “Regulation of thrombin-serpin inhibition reactions by a thrombin-specific RNA aptamer.” In Faseb Journal, 16:A1193–A1193. FEDERATION AMER SOC EXP BIOL, 2002.Link to Item
-
White, R. R., C. P. Rusconi, B. A. Sullenger, and C. D. Kontos. “A novel inhibitor of Angiopoietin-1 disrupts Tie2-mediated endothelial cell survival.” In Circulation, 104:315–315. LIPPINCOTT WILLIAMS & WILKINS, 2001.Link to Item
-
Rusconi, C. P., A. Yeh, H. K. Lyerly, J. H. Lawson, and B. A. Sullenger. “RNA aptamers as potential anticoagulants directed against factor VIIa function.” In Thrombosis and Haemostasis, 468–468. F K SCHATTAUER VERLAG GMBH, 1999.Link to Item
-
SULLENGER, B. A. “RIBOZYME-MEDIATED REPAIR OF DEFECTIVE MESSENGER-RNAS BY TARGETED TRANSSPLICING - RNA BASED MOLECULAR SURGERY.” In Journal of Cellular Biochemistry, 206–206. WILEY-LISS, 1995.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.